Metformin, Statin Use, and Female Colorectal Cancer: A Population-Based Cohort Study in Taiwan

In the last few years, the incidence of colorectal cancer (CRC) in women has gradually increased. However, epidemiological studies on the relationship between type II diabetes mellitus (T2DM) and female CRC and the effect of metformin or statins on female CRC are insufficient. To determine their association, we conducted a population-based cohort study on women in Taiwan. We collected data on a total of 396,521 women aged 40 to 64 years old from 1 January 2007 to 31 December 2009 from the National Health Insurance Research Database. We followed up on all participants in the cohort until the occurrence of CRC, the date for all death, or 31 December 2015. Full development of CRC was identified using the International Classification of Disease (ICD), 9th Revision, code 153. We estimated hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) using the Cox proportional hazards model. Both metformin (adjusted hazard ratio, aHR = 1.12; 95% CI: 0.934-1.335, p = 0.227) and statin (aHR = 1.03; 95% CI: 0.906-1.172, p = 0.645) use showed no association with female CRC in a multivariate analysis. The findings indicate that metformin and statin use showed no protective effect against female colorectal cancer (CRC). An additional randomized trial is necessary to investigate the effect of metformin and statin use in CRC prevention.

Automated summary

In a population-based cohort study conducted in Taiwan, it was found that the use of metformin and statins showed no association with female colorectal cancer (CRC) and did not provide a protective effect against it. The researchers suggested that an additional randomized trial is needed to investigate the effect of these drugs in CRC prevention.